埃索美拉唑与奥美拉唑在幽门螺杆菌相关性胃溃疡治疗中的应用效果对比分析(1)
[摘要] 目的 探讨在幽门螺杆菌(HP)相关性胃溃疡的治疗中采取埃索美拉唑与奥美拉唑的应用效果。方法 方便选取在该院消化内科近期(2016年1月—2018年12月时期)收治以幽门螺旋杆菌相关性胃溃疡为诊断的患者总计300例，随机数字法分成对照组(150例)与实验组(150例)，对照组采用奥美拉唑治疗，实验组采用埃索美拉唑治疗。对照两组患者临床治疗效果、并发症发生率、HP清除率、临床症状消失时间。结果 实验组患者上腹部疼痛、嗳气、反酸恶心、烧灼感症状消失时间明显少于对照组，差异有统计学意义(t=26.626，P=0.000;t=16.528，P=0.000;t=22.328，P=0.000;t=14.309，P=0.000)。实验组患者总有效率为92.00%，HP转阴率为82.00%，并发症发生率为4.67%，对照组分别为80.67%、64.67%、18.67%，差异有统计学意义(χ2=8.165，P=0.004;χ2=13.524，P=0.001;χ2=18.531，P=0.001)。結论 在幽门螺旋杆菌相关性胃溃疡的治疗中，应用埃索美拉唑治疗，可明显缩短病程，提高临床治疗效果与HP清除率，减少不良反应的发生，效果理想。
, http://www.100md.com
[关键词] 埃索美拉唑;奥美拉唑;幽门螺旋杆菌;相关性胃溃疡;应用效果分析
[中图分类号] R573.1 [文献标识码] A [文章编号] 1674-0742(2019)07(a)-0100-03
Comparative Analysis of the Effects of Esomeprazole and Omeprazole in the Treatment of Helicobacter Pylori-associated Gastric Ulcer
WU Wen， ZHANG Heng-bin， LIAO Xiao-hong
Department of Gastroenterology， Baoan District Central Hospital， Shenzhen， Guangdong Province， 518000 China
, 百拇医药
[Abstract] Objective To observe the effect of esomeprazole and omeprazole in the treatment of Helicobacter pylori (HP)-associated gastric ulcer. Methods A total of 300 patients with Helicobacter pylori-associated gastric ulcer were diagnosed in our hospital recently in the Department of Gastroenterology (January 2016-to-December 2018). The patients were convenient divided into the control group (150 cases) and the experimental group (150 cases) by random number method， the control group was treated with omeprazole， and the experimental group was treated with esomeprazole. The clinical treatment effect， complication rate， HP clearance rate and clinical symptom disappearance time of the two groups were compared. Results In the experimental group， the disappearance time of upper abdominal pain， hernia， acid-lowering nausea and burning sensation was significantly less than that of the control group. The difference was statistically significant (t=26.626， P=0.000; t=16.528， P=0.000; t=22.328， P=0.000; t=14.309， P=0.000). In the experimental group， the total effective rate was 92.00%， the HP conversion rate was 82.00%， the complication rate was 4.67%， and the control group was 80.67%， 64.67%， and 18.67%， respectively. The difference was statistically significant (χ2=8.165， P=0.004; χ2=13.524， P=0.001; χ2=18.531， P=0.001). Conclusion In the treatment of Helicobacter pylori-associated gastric ulcer， the treatment with esomeprazole can significantly shorten the course of disease， improve the clinical treatment effect and HP clearance rate， and reduce the occurrence of adverse reactions., 百拇医药(伍文 张恒斌 廖晓宏)
, http://www.100md.com
[关键词] 埃索美拉唑;奥美拉唑;幽门螺旋杆菌;相关性胃溃疡;应用效果分析
[中图分类号] R573.1 [文献标识码] A [文章编号] 1674-0742(2019)07(a)-0100-03
Comparative Analysis of the Effects of Esomeprazole and Omeprazole in the Treatment of Helicobacter Pylori-associated Gastric Ulcer
WU Wen， ZHANG Heng-bin， LIAO Xiao-hong
Department of Gastroenterology， Baoan District Central Hospital， Shenzhen， Guangdong Province， 518000 China
, 百拇医药
[Abstract] Objective To observe the effect of esomeprazole and omeprazole in the treatment of Helicobacter pylori (HP)-associated gastric ulcer. Methods A total of 300 patients with Helicobacter pylori-associated gastric ulcer were diagnosed in our hospital recently in the Department of Gastroenterology (January 2016-to-December 2018). The patients were convenient divided into the control group (150 cases) and the experimental group (150 cases) by random number method， the control group was treated with omeprazole， and the experimental group was treated with esomeprazole. The clinical treatment effect， complication rate， HP clearance rate and clinical symptom disappearance time of the two groups were compared. Results In the experimental group， the disappearance time of upper abdominal pain， hernia， acid-lowering nausea and burning sensation was significantly less than that of the control group. The difference was statistically significant (t=26.626， P=0.000; t=16.528， P=0.000; t=22.328， P=0.000; t=14.309， P=0.000). In the experimental group， the total effective rate was 92.00%， the HP conversion rate was 82.00%， the complication rate was 4.67%， and the control group was 80.67%， 64.67%， and 18.67%， respectively. The difference was statistically significant (χ2=8.165， P=0.004; χ2=13.524， P=0.001; χ2=18.531， P=0.001). Conclusion In the treatment of Helicobacter pylori-associated gastric ulcer， the treatment with esomeprazole can significantly shorten the course of disease， improve the clinical treatment effect and HP clearance rate， and reduce the occurrence of adverse reactions., 百拇医药(伍文 张恒斌 廖晓宏)